Advancing science, sharing knowledge

Okomera strengthens its leadership team with the appointment of Marion Ghibaudo as Chief Technology Officer. An expert in scaling medical innovations, Marion joins Okomera as the company advances toward industrial deployment.

​

Selected from more than 700 applications, Okomera is proud to join the EIC Advanced Innovation Challenge, one of Europe’s most competitive innovation funding programs. A significant milestone : it recognizes Okomera’s ability to turn breakthrough innovation into a credible path to market supported by the right ecosystem.

​

Okomera CEO Silvère Lucquin was recently featured on BFM Business alongside Cécile Tharaud from Polytechnique Ventures, providing an great opportunity to highlight Okomera’s innovative approach to personalized cancer treatment. Discover the full BFM Business interview and learn how Okomera is bringing functional testing to precision oncology.

​

Join Okomera at SLAS 2026, Booth #2044! The SLAS International Conference is the flagship annual conference presented by The Society for Laboratory Automation and Screening, a leading international professional society of academic, industry and government researchers as well as developers and providers of laboratory automation technology and tools.

​

Exclusive webinar featuring a case study conducted by Gustave Roussy (IGR) research team, presented by Lucile Mercier, IGR & Okomera, together with Jaehyeok Lee, Tomocube. Join us to see how holotomography + microfluidics enable powerful patient-derived organoid drug screening workflows.

​

In collaboration with Tomocube and Gustave Roussy, Okomera has released a new application note demonstrating how integrating imaging with automated functional assays opens new possibilities for precision oncology and patient-tailored drug testing. Download full case study :

​

Meet Okomera at ESMO - European Society for Medical Oncology 2025, Booth G07. The ESMO Congress stands as a premier global oncology platform, bringing together clinicians, researchers, patient advocates, journalists, and healthcare industry representatives from around the world: 37.000 participants, 174 countries and territories, 661 speakers, 2.927 abstracts presented.

​

Okomera is participating to ELRIG’s Drug Discovery 2025, booth G07. Hosted by the city of Liverpool, ELRIG’s Drug Discovery is one of Europe’s leading drug discovery and life sciences conference with scientific tracks covering topics including robotics, cell and disease models, omics, AI, oncology and neurodegenerative disease.

​

Okomera is pleased to announce that Silvère Lucquin has been appointed Chief Executive Officer of Okomera. With 10+ years in MedTech and Life Science tools, Silvère has led high- growth teams and platforms, with a proven record of scaling innovation across strategy, operations, partnerships, and product. Silvère will lead Okomera's next phase of growth, driving pilot studies with key partners, advancing industrialization, and preparing for commercial launch.

​

Article published in iScience. Tittle: Combinatorial drug screening on 3D Ewing sarcoma spheroids using droplet-based microfluidics. Authors: Romain Fevre, Gaëtan Mary, Nadia Vertti-Quintero, Aude Durand, Raphaël F.-X. Tomasi, Elaine Del Nery, Charles N. Baroud.

​

Article published in the Exploration of Targeted Anti-tumor Therapy Journal. Tittle: Evaluating immune response in vitro in a relevant microenvironment: a high-throughput microfluidic model for clinical screening. Authors: Flora Doffe, Layla Fuoco, Judith Michels, Sandra Jernström, Raphael Tomasi, Pierre Savagner.

​

Article published in Nature Communications. Title: High resolution microfluidic assay and probabilistic modeling reveal cooperation between T cells in tumor killing. Authors: Gustave Ronteix, Shreyansh Jain, Christelle Angely, Marine Cazaux, Roxana Khazen, Philippe Bousso & Charles N. Baroud.

​